
|Videos|November 14, 2014
The Evolving Role of Chemotherapy for Hormone-Sensitive Prostate Cancer
Author(s)Christopher Sweeney, MBBS
Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the evolving role of chemotherapy for hormone-sensitive prostate cancer.
Advertisement
Clinical Pearls
Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the evolving role of chemotherapy for hormone-sensitive prostate cancer.
- Oncologists have been trained in the use of chemotherapy — they are aware of the side effects.
- The side effect profile of chemotherapy is essentially the same as when used for castration-resistant disease.
- The question remains: Is there a difference in using docetaxel in the hormone-sensitive or castration-resistant settings?
- The rate of neutropenic fever was slightly higher in the CHAARTED study (8%) compared with the TAX 327 study (3%).
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5










































